As part of its investigation, the Competition and Markets Authority (CMA) "provisionally" found last year that the pharmaceutical company charged the NHS more than £34 million for liothyronine tablets in 2016 – "an increase from around £600,000" spent on them in 2006, it announced yesterday (November 21).
Free to registered users
Register to gain full access to C+D and C+D Community content
Already registered?